> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Alucent Trial for Vascular Disease
- URL: https://www.fdaweb.com/fda-approves-alucent-trial-for-vascular-disease/
- Published: 2017-05-16T12:00:00.000Z
- Updated: 2026-09-14T22:23:39.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5138706

FDA has approved an Alucent Medical Phase 1 clinical trial of Natural Vascular Scaffolding (NVS), a novel combination drug/device therapy for treating peripheral vascular disease. The current standard of care for peripheral vascular disease relies on percutaneous balloon angioplasty, in which balloons are coated with known antiproliferative drugs such as paclitaxel, and metallic stents, according to the company. Alucent says these treatments often lead to recurrence of the target lesion and the need for retreatment. NVS is designed as a photo-activated drug therapy that helps build natural scaffolding to“ keep the vessel open durably, possibly replacing the need for an implanted stent,” it says. The Phase 1 study will begin this summer at three locations across the U.S.